Instrument NameAbcellera Biologics IncInstrument Symbol(ABCL-Q)

Instrument ExchangeNASDAQ

ABCL earnings call for the period ending September 30, 2024.

With significant insider purchases and high-profile hedge fund interest, AbCellera is one penny stock to watch.

ABCL earnings call for the period ending June 30, 2024.

Down 96% from all-time highs, AbCellera Biologics is a biotech stock with massive upside potential, given consensus price target estimates.

The Baker brothers are billionaires with a successful track record in the biopharmaceutical industry.

Wall Street analysts say this drug developer can more than double your money.

ABCL earnings call for the period ending March 31, 2024.

The pharma sector is expected to undergo a huge disruption, thanks to the impact of artificial intelligence. Here are three companies that Wall Street analysts think could benefit, based on their AI-driven R&D.

A luxury clothing company continues to be the biggest target

ABCL earnings call for the period ending December 31, 2023.

Healthcare stocks have underperformed in 2023, but that is expected to change this year.

These innovation-oriented companies could take flight this year.

Company still in ‘fantastic’ financial condition with more than US$1-billion in liquidity: CEO

A filing to the U.S. SEC said the layoffs and reorganization will help AbCellera ‘focus its efforts toward the clinical development of new antibody medicines for patients’

ABCL earnings call for the period ending September 30, 2023.

Argenx's chart is forming a bullish base after a 28% jump after positive clinical trials. Analysts believe the immunology specialist is an acquisition target.

ABCL earnings call for the period ending June 30, 2023.

ABCL earnings call for the period ending March 31, 2023.

AbCellera (Nasdaq: ABCL) today announced financial results for the first quarter of 2023. All financial information in this press release is reported in U.S. dollars, unless otherwise indicated.